EVIDENCE LIBRARY
Remimazolam Case Involved an Older Patient With a Homozygous RYR1 Variant and Prior Fulminant Reaction
A genetically characterized patient had an uncomplicated remimazolam-based anesthetic. The case cannot establish population-wide safety or separate the drug from the complete precaution plan.
A genetically characterized patient had an uncomplicated remimazolam-based anesthetic. The case cannot establish population-wide safety or separate the drug from the complete precaution plan.
The reported course
An eighty-year-old man had a previous fulminant malignant-hyperthermia episode and confirmed susceptibility testing. Genetic analysis identified a homozygous likely pathogenic RYR1 variant.
For laparoscopic surgery, clinicians used remimazolam, remifentanil, and rocuronium with close monitoring and immediate dantrolene availability. Temperature, carbon dioxide, and hemodynamics remained stable, and recovery was uneventful.
What one success establishes
The report supplies a carefully described example, not an adverse-event frequency or comparison against another intravenous regimen. Preparation, avoidance of triggers, monitoring, and patient characteristics all contributed to the context.
Laboratory calcium findings discussed in the background are separate from this clinical observation. Neither establishes that every RYR1 variant responds identically. A forensic opinion should preserve the entire management sequence and distinguish feasibility in this patient from proof that any individual complication would have been prevented by choosing remimazolam.
Source paper
Original analysis of the supplied journal article, identified as PMC13235414.